Kraig Biocraft Laboratories(OTC) KBLB

Kraig Labs creates strong, protein-based fibers for technical textiles. Its fibers aim to improve safety gear and industrial materials. The company’s work targets military, medical, and industrial users needing advanced materials.

Spider Silk and Friends: What’s on Offer?

• Recombinant Spider Silk Fibers: Engineered silkworms produce spider silk proteins for use in protective gear and industrial textiles. (0% of revenue; pre-commercial)
• Ballistic Protection Materials: Fibers designed for military and police body armor, offering lightweight strength. (0% of revenue)
• Industrial and Safety Applications: Used in cables, abrasion-resistant parts, and safety equipment for factories and infrastructure. (0% of revenue)
• Medical and Filtration Textiles: Fibers for medical devices, wound care, and filtration systems. (0% of revenue)
• Composite Materials: Components for aerospace, transportation, and construction, enhancing durability and flexibility. (0% of revenue)

Growth Moves: Silk Road Edition

• Signed partnership with Vietnam Sericulture Association and Lam Dong Agro-Forestry Research & Experiment Center in January 2024 to expand production.
• Received new investment and registration certificates for Vietnam operations in January 2025.
• Leased new production facilities in Lam Dong, Vietnam, to scale up output in 2025.
• Entered Standby Equity Purchase Agreement in January 2025, enabling up to $10 million in stock sales for funding.

Why Kraig Labs Is a Bit Different

Kraig Labs uses genetic engineering to create silkworms that spin spider silk, a material known for its strength and flexibility. The company’s production model leverages existing silk industry infrastructure, especially in Vietnam. Its focus on natural, non-petrochemical fibers appeals to industries seeking sustainable materials.

Five Things You Need to Know

• No commercial revenue reported for Q2 2025 or prior periods.
• Net loss was $726,133 in Q2 2025, down 54.8% from Q2 2024.
• Operating expenses fell 57.1% year-over-year in Q2 2025.
• Cash and equivalents were $785,462 as of June 30, 2025.
• Working capital deficit stood at $9.19 million as of June 30, 2025.

Bottom Line

Kraig Labs remains in the research and development phase, focusing on scaling production and reducing costs. The company’s future depends on successful commercialization and continued access to funding.